Related Experiment Video
Updated: Jul 10, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Differences in antitumor effects of various statins on human pancreatic cancer
Helena Gbelcová1, Martin Lenícek, Jaroslav Zelenka
1Department of Biochemistry and Microbiology and Center for Applied Genomics, Institute of Chemical Technology, Prague, Czech Republic.
Abstract:
Statins are widely used for the treatment of hypercholesterolemia. However, their inhibitory action on HMG-CoA reductase also results in the depletion of intermediate biosynthetic products, which importantly contribute to cell proliferation. The aim of the present study was to compare the effects of the individual commercially available statins on experimental pancreatic cancer. The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human pancreatic cancer were evaluated in CAPAN-2, BxPc-3 and MiaPaCa-2 cell lines. The in vivo experiments were performed on nude mice xenotransplanted with CAPAN-2 cells. The mice received oral treatments either with a placebo, or with the statins mentioned earlier in a daily dose corresponding to a hypocholesterolemic dose in humans. The effect of these statins on the intracellular Ras protein, trafficking in MiaPaCa-2 transfected cells, was also investigated. Substantial differences in the tumor-suppressive effects of all statins were detected in both in vitro and in vivo experiments. While simvastatin exerted the highest tumor-suppressive effects in vitro, rosuvastatin (p = 0.002), cerivastatin (p = 0.002) and fluvastatin (p = 0.009) were the most potent compounds in an animal model. All statins (except pravastatin) inhibited intracellular Ras protein translocation. In summary, substantial tumor-suppressive effects of various statins on the progression of experimental pancreatic adenocarcinoma were demonstrated, with marked differences among individual statins. These results support greatly the potential of statins for the chemoadjuvant treatment of pancreatic cancer.
Insights
This study found that different statins show varying effectiveness in suppressing pancreatic cancer growth in lab and animal models. Some statins significantly inhibited tumor progression and Ras protein activity, suggesting their potential as cancer treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Statins, primarily used for hypercholesterolemia, inhibit HMG-CoA reductase, impacting cell proliferation.
- The depletion of essential biosynthetic products by statins warrants investigation into their anti-cancer properties.
Purpose of the Study:
- To compare the efficacy of various commercially available statins against experimental pancreatic cancer.
- To evaluate statin effects on pancreatic cancer cell viability, tumor growth in vivo, and Ras protein translocation.
Main Methods:
- In vitro assessment of statin effects on human pancreatic cancer cell lines (CAPAN-2, BxPc-3, MiaPaCa-2).
- In vivo studies using nude mice xenotransplanted with CAPAN-2 cells, treated orally with different statins.
- Investigation of statin impact on intracellular Ras protein trafficking.
Main Results:
- Significant variations in tumor-suppressive effects were observed among statins in both in vitro and in vivo models.
- Simvastatin demonstrated the strongest in vitro tumor suppression, while rosuvastatin, cerivastatin, and fluvastatin were most potent in vivo.
- Most statins (excluding pravastatin) effectively inhibited Ras protein translocation.
Conclusions:
- Individual statins exhibit distinct tumor-suppressive capabilities against pancreatic adenocarcinoma progression.
- The findings highlight the potential of statins as chemoadjuvant agents for pancreatic cancer therapy.
